- YMAB Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Y-mAbs Therapeutics (YMAB) 8-K25 Nov 20FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of NeuroblastomaFinancial data
Company Profile